Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Study Identifier
CMO-US-ID-0476
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Results Available
Protocol
Available Language(s): English
Statistical Analysis Plan
Available Language(s): English
Study Details
Medical Condition
Study Drug
Phase
Phase 4
Sex
Female & Male
Age
18+ years
Protocol Summary
This study will evaluate a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) for the treatment of ABSSSI compared to usual care.
Study Locations
Location
Status
Location
Maricopa Medical Center
Phoenix, Arizona, United States, 85008
Status
Not applicable
Location
Olive View-UCLA Medical Center
Sylmar, California, United States, 91342
Status
Not applicable
Location
Hartford Hospital
Hartford, Connecticut, United States, 06102
Status
Not applicable
Location
Tampa General Hospital
Tampa, Florida, United States, 33606
Status
Not applicable
Location
Rush University Medical Center
Chicago, Illinois, United States, 60612
Status
Not applicable
Location
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
Status
Not applicable
Showing {first} - {last} of {total} Results